Press Releases

Date Title    
Toggle Summary Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares
Toggle Summary Editas Medicine Announces Pricing of Initial Public Offering
Toggle Summary Editas Medicine Appoints John D. Mendlein, Ph.D., to Board of Directors
Toggle Summary Editas Medicine Expands Leadership Team with Key Organizational Appointments
Toggle Summary Editas Medicine Comments in Connection with International Summit on Human Gene Editing
Toggle Summary Editas Medicine Raises $120 Million to Advance Genome Editing
Toggle Summary Editas Medicine Named A 2015 Technology Pioneer by World Economic Forum
Toggle Summary Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer
Toggle Summary Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies
Toggle Summary Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference
Toggle Summary Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting
Toggle Summary Vic Myer, Ph.D. Joins Editas Medicine as Chief Technology Officer
Toggle Summary Editas Medicine Reports Data Demonstrating the Potential of CRISPR/Cas9 to Enable Gene Repair Through a New Mechanism
Toggle Summary Editas Medicine Reports New Data Characterizing Novel Properties of Staphylococcus aureus Cas9 as a Tool for CRISPR-Based Genome Engineering
Toggle Summary Editas Medicine Licenses Genome Editing Technology from Broad Institute and Harvard University
Toggle Summary Editas Medicine Licenses Genome Editing Technology from Duke University
Toggle Summary Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital
Toggle Summary FierceBiotech names Editas Medicine as one of its “Fierce 15” Biotech Companies of 2014
Toggle Summary Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer
Toggle Summary Editas Medicine Selected for Hottest Healthcare Startup at the New England Venture Capital Association’s 2014 NEVY Awards
Toggle Summary Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers
Toggle Summary Broad Institute awarded first patent for engineered CRISPR-Cas9 system
Toggle Summary Broad, MIT researchers reveal structure of key CRISPR complex
Toggle Summary Editas Medicine Co-founder Publishes High-Resolution Structures of MajorCas9 Enzymes in Science
Toggle Summary Editas Medicine Co-founder Develops Novel Approach to Increase Specificity of CRISPR/Cas9 Technology; Findings Published in Nature Biotechnology
Toggle Summary Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics